BBHC
LAB icon

Brown Brothers Harriman & Co’s Standard BioTools LAB Stock Holding History

Brown Brothers Harriman & Co’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,307
Closed -$3K – 1393
2022
Q3 		$3K Buy
+2,307
New +$3.49K ﹤0.01% 1376

Other funds holding LAB

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JCP
Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Brown Brothers Harriman & Co's LAB Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Standard BioTools (LAB) in Q4 2022, closing a stake of 2,307 shares — an estimated $3K sold.

Brown Brothers Harriman & Co first reported a position in LAB in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 68 funds tracked by Wall St. Rank hold LAB as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Standard BioTools position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 2,307 Standard BioTools shares in Q4 2022, an estimated $3K.
  • Brown Brothers Harriman & Co first reported a position in Standard BioTools in Q3 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Standard BioTools position peaked at $3K in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.